A decades-long investigation of acute metabolism-based hepatotoxicity by herbal constituents: a case study of pennyroyal oil

References

• Anderson IB, Mullen WH, Meeker JE, et al. (1996). Pennyroyal toxicity: Measurement of toxic metabolite levels in two cases and review of the literature. Ann Intern Med 124:726–734
   PubMed Web of Science ®Google Scholar
• Bakerink JA, Gospe SM Jr, Dimand RJ, Eldridge MW. (1996). Multiple organ failure after ingestion of pennyroyal oil from herbal tea in two infants. Pediatrics 98:944–947
   PubMed Web of Science ®Google Scholar
• Bunchorntavakul C, Reddy KR. (2013). Review article: Herbal and dietary supplement hepatotoxicity. Aliment Pharmacol Ther 37:3–17
   PubMed Web of Science ®Google Scholar
• Chen LJ, Lebetkin EH, Burka LT. (2001). Metabolism of (R)-(+)-pulegone in F344 rats. Drug Metab Dispos 29:1567–1577
   PubMed Web of Science ®Google Scholar
• Chen LJ, Lebetkin EH, Burka LT. (2003a). Comparative disposition of (R)-(+)-pulegone in B6C3F1 mice and F344 rats. Drug Metab Dispos 31:892–899
   PubMed Web of Science ®Google Scholar
• Chen LJ, Lebetkin EH, Burka LT. (2003b). Metabolism of (R)-(+)-menthofuran in Fischer-344 rats: Identification of sulfonic acid metabolites. Drug Metab Dispos 31:1208–1213
   PubMed Web of Science ®Google Scholar
• Eisenberg DM, Kessler RC, van Rompay MI, et al. (2001). Perceptions about complementary therapies relative to conventional therapies among adults who use both: Results from a national survey. Ann Intern Med 135:344–351
   PubMed Web of Science ®Google Scholar
• Gold J, Cates W Jr. (1980). Herbal abortifacients. JAMA 243:1365–1366
   PubMed Web of Science ®Google Scholar
• Gordon WP, Forte AJ, McMurtry RJ, et al. (1982). Hepatotoxicity and pulmonary toxicity of pennyroyal oil and its constituent terpenes in the mouse. Toxicol Appl Pharmacol 65:413–424
   PubMed Web of Science ®Google Scholar
• Gordon WP, Huitric AC, Seth CL, et al. (1987). The metabolism of the abortifacient terpene, (R)-(+)-pulegone, to a proximate toxin, menthofuran. Drug Metab Dispos 15:589–594
   PubMed Web of Science ®Google Scholar
• Gunby P. (1979). Plant known for centuries still causes problems today. JAMA 241:2246–2247
   PubMedGoogle Scholar
• Khojasteh SC, Hartley DP, Ford KA, et al. (2012). Characterization of rat liver proteins adducted by reactive metabolites of menthofuran. Chem Res Toxicol 25:2301–2309
   PubMed Web of Science ®Google Scholar
• Khojasteh SC, Oishi S, Nelson SD. (2010). Metabolism and toxicity of menthofuran in rat liver slices and in rats. Chem Res Toxicol 23:1824–1832
   PubMed Web of Science ®Google Scholar
• Khojasteh-Bakht SC, Chen W, Koenigs LL, et al. (1999a). Metabolism of (R)-(+)-pulegone and (R)-(+)-menthofuran by human liver cytochrome P-450s: Evidence for formation of a furan epoxide. Drug Metab Dispos 27:574–580
   PubMed Web of Science ®Google Scholar
• Khojasteh-Bakht SC, Koenigs LL, Peter RM, et al. (1998). (R)-(+)-menthofuran is a potent, mechanism-based inactivator of human liver cytochrome P450 2A6. Drug Metab Dispos 26:701–704
   PubMed Web of Science ®Google Scholar
• Khojasteh-Bakht SC, Nelson SD, Atkins WM. (1999b). Glutathione S-transferase catalyzes the isomerization of (R)-2-hydroxymenthofuran to mintlactones. Arch Biochem Biophys 370:59–65
   PubMed Web of Science ®Google Scholar
• Madyastha KM, Gaikwad NW. (1999). Metabolic disposition of a monoterpene ketone, piperitenone, in rats: Evidence for the formation of a known toxin, p-cresol. Drug Metab Dispos 27:74–80
   PubMed Web of Science ®Google Scholar
• Madyastha KM, Raj CP. (1993). Studies on the metabolism of a monoterpene ketone, R-(+)-pulegone – A hepatotoxin in rat: Isolation and characterization of new metabolites. Xenobiotica 23:509–518
   PubMed Web of Science ®Google Scholar
• Madyastha KM, Raj CP. (2002). Stereoselective hydroxylation of 4-methyl-2-cyclohexenone in rats: Its relevance to R-(+)-pulegone-mediated hepatotoxicity. Biochem Biophys Res Commun 297:202–205
   PubMed Web of Science ®Google Scholar
• McClanahan RH, Thomassen D, Slattery JT, Nelson SD. (1989). Metabolic activation of (R)-(+)-pulegone to a reactive enonal that covalently binds to mouse liver proteins. Chem Res Toxicol 2:349–355
   PubMed Web of Science ®Google Scholar
• Mizutani T, Nomura H, Nakanishi K, Fujita S. (1987). Effects of drug metabolism modifiers on pulegone-induced hepatotoxicity in mice. Res Commun Chem Pathol Pharmacol 58:75–83
   PubMedGoogle Scholar
• Moorthy B, Madyastha P, Madyastha KM. (1989a). Hepatotoxicity of pulegone in rats: Its effects on microsomal enzymes, in vivo. Toxicology 55:327–337
   PubMed Web of Science ®Google Scholar
• Moorthy B, Madyastha P, Madyastha KM. (1989b). Metabolism of a monoterpene ketone, R-(+)-pulegone – A hepatotoxin in rat. Xenobiotica 19:217–224
   PubMed Web of Science ®Google Scholar
• Nelson SD, McClanahan RH, Thomassen D, et al. (1992). Investigations of mechanisms of reactive metabolite formation from (R)-(+)-pulegone. Xenobiotica 22:1157–1164
   PubMed Web of Science ®Google Scholar
• Stedman C. (2002). Herbal hepatotoxicity. Semin Liver Dis 22:195–206
   PubMed Web of Science ®Google Scholar
• Sullivan JB Jr, Rumack BH, Thomas H Jr, et al. (1979). Pennyroyal oil poisoning and hepatotoxicity. JAMA 242:2873–2874
   PubMed Web of Science ®Google Scholar
• Sztajnkrycer MD, Otten EJ, Bond GR, et al. (2003). Mitigation of pennyroyal oil hepatotoxicity in the mouse. Acad Emerg Med 10:1024–1028
   PubMed Web of Science ®Google Scholar
• Thomassen D, Pearson PG, Slattery JT, Nelson SD. (1991). Partial characterization of biliary metabolites of pulegone by tandem mass spectrometry. Detection of glucuronide, glutathione, and glutathionyl glucuronide conjugates. Drug Metab Dispos 19:997–1003
   PubMed Web of Science ®Google Scholar
• Thomassen D, Slattery JT, Nelson SD. (1988). Contribution of menthofuran to the hepatotoxicity of pulegone: Assessment based on matched area under the curve and on matched time course. J Pharmacol Exp Ther 244:825–829
   PubMed Web of Science ®Google Scholar
• Vallance WB. (1955). Pennyroyal poisoning: A fatal case. Lancet 269:850–851
   PubMedGoogle Scholar